199 related articles for article (PubMed ID: 23570303)
1. A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function.
Kamburova EG; Koenen HJ; Borgman KJ; ten Berge IJ; Joosten I; Hilbrands LB
Am J Transplant; 2013 Jun; 13(6):1503-11. PubMed ID: 23570303
[TBL] [Abstract][Full Text] [Related]
2. In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells.
Kamburova EG; Koenen HJ; Boon L; Hilbrands LB; Joosten I
Am J Transplant; 2012 Feb; 12(2):341-50. PubMed ID: 22070501
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal analysis of T and B cell phenotype and function in renal transplant recipients with or without rituximab induction therapy.
Kamburova EG; Koenen HJ; van den Hoogen MW; Baas MC; Joosten I; Hilbrands LB
PLoS One; 2014; 9(11):e112658. PubMed ID: 25393622
[TBL] [Abstract][Full Text] [Related]
4. Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons: depletion of CD20- and CD22-positive B cells does not result in significantly decreased production of anti-alphaGal antibody.
Alwayn IP; Xu Y; Basker M; Wu C; Buhler L; Lambrigts D; Treter S; Harper D; Kitamura H; Vitetta ES; Abraham S; Awwad M; White-Scharf ME; Sachs DH; Thall A; Cooper DK
Xenotransplantation; 2001 Aug; 8(3):157-71. PubMed ID: 11472623
[TBL] [Abstract][Full Text] [Related]
5. A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation.
Zarkhin V; Li L; Kambham N; Sigdel T; Salvatierra O; Sarwal MM
Am J Transplant; 2008 Dec; 8(12):2607-17. PubMed ID: 18808404
[TBL] [Abstract][Full Text] [Related]
6. Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis.
Rehnberg M; Amu S; Tarkowski A; Bokarewa MI; Brisslert M
Arthritis Res Ther; 2009; 11(4):R123. PubMed ID: 19686595
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamics of rituximab in kidney allotransplantation.
Genberg H; Hansson A; Wernerson A; Wennberg L; Tydén G
Am J Transplant; 2006 Oct; 6(10):2418-28. PubMed ID: 16925569
[TBL] [Abstract][Full Text] [Related]
8. Chronic antibody-mediated rejection is reduced by targeting B-cell immunity during an introductory period.
Kohei N; Hirai T; Omoto K; Ishida H; Tanabe K
Am J Transplant; 2012 Feb; 12(2):469-76. PubMed ID: 22054413
[TBL] [Abstract][Full Text] [Related]
9. Discrepancy of B cell frequency between periphery and spleen after rituximab treatment in ABO-incompatible liver transplantation.
Iso Y; Sawada T; Kita J; Shiraki T; Sakuraoka Y; Kato M; Shimoda M; Kubota K
Hepatogastroenterology; 2013 Oct; 60(127):1624-6. PubMed ID: 24634932
[TBL] [Abstract][Full Text] [Related]
10. Rituximab in pediatric renal transplantation: a treatment for allograft rejection with B-cell infiltrates?
Zand MS
Am J Transplant; 2008 Dec; 8(12):2489-90. PubMed ID: 19032220
[No Abstract] [Full Text] [Related]
11. Rituximab in immunologic glomerular diseases.
Ejaz AA; Asmar A; Alsabbagh MM; Ahsan N
MAbs; 2012; 4(2):198-207. PubMed ID: 22377738
[TBL] [Abstract][Full Text] [Related]
12. B cell survival in intragraft tertiary lymphoid organs after rituximab therapy.
Thaunat O; Patey N; Gautreau C; Lechaton S; Fremeaux-Bacchi V; Dieu-Nosjean MC; Cassuto-Viguier E; Legendre C; Delahousse M; Lang P; Michel JB; Nicoletti A
Transplantation; 2008 Jun; 85(11):1648-53. PubMed ID: 18551073
[TBL] [Abstract][Full Text] [Related]
13. Development of B-cell memory in early childhood and the impact on antigen-specific tolerance after heart transplantation.
Urschel S; Ryan LA; M Larsen I; Biffis K; Dijke IE; West LJ
J Heart Lung Transplant; 2016 Apr; 35(4):491-9. PubMed ID: 26856666
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of rituximab dosage for ABO-incompatible living-donor kidney transplantation.
Nakao T; Ushigome H; Kawai K; Nakamura T; Harada S; Koshino K; Suzuki T; Ito T; Nobori S; Yoshimura N
Transplant Proc; 2015 Apr; 47(3):644-8. PubMed ID: 25891703
[TBL] [Abstract][Full Text] [Related]
15. Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys.
Schröder C; Azimzadeh AM; Wu G; Price JO; Atkinson JB; Pierson RN
Transpl Immunol; 2003; 12(1):19-28. PubMed ID: 14551029
[TBL] [Abstract][Full Text] [Related]
16. Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response.
Nakou M; Katsikas G; Sidiropoulos P; Bertsias G; Papadimitraki E; Raptopoulou A; Koutala H; Papadaki HA; Kritikos H; Boumpas DT
Arthritis Res Ther; 2009; 11(4):R131. PubMed ID: 19715572
[TBL] [Abstract][Full Text] [Related]
17. Rituximab in renal transplantation.
Barnett AN; Hadjianastassiou VG; Mamode N
Transpl Int; 2013 Jun; 26(6):563-75. PubMed ID: 23414100
[TBL] [Abstract][Full Text] [Related]
18. Effect of Different Rituximab Doses on B Cell Count, Anti-A/B Antibody Titer, Graft Function, and Infectious Complications in ABO-Incompatible Renal Transplantation: A Prospective Study.
Thukral S; Shinde N; Ray DS
Transplant Proc; 2021 Apr; 53(3):970-975. PubMed ID: 33279260
[TBL] [Abstract][Full Text] [Related]
19. Preemptive CD20+ B cell depletion attenuates cardiac allograft vasculopathy in cyclosporine-treated monkeys.
Kelishadi SS; Azimzadeh AM; Zhang T; Stoddard T; Welty E; Avon C; Higuchi M; Laaris A; Cheng XF; McMahon C; Pierson RN
J Clin Invest; 2010 Apr; 120(4):1275-84. PubMed ID: 20335656
[TBL] [Abstract][Full Text] [Related]
20. Different sensitivity of rituximab-treatment to B-cells between ABO-incompatible kidney and liver transplantation.
Morimoto H; Ide K; Tanaka Y; Ishiyama K; Ohira M; Tahara H; Akita T; Tanaka J; Ohdan H
Hum Immunol; 2016 Jun; 77(6):456-63. PubMed ID: 27085793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
